Thinking about the possibility of cancer can be overwhelming, but taking steps to find cancer early
can help you feel more in control. In fact, when cancers are diagnosed early before they have had a chance to spread, the overall 5-year survival rate is 4x higher than when they are diagnosed in later stages. The Galleri™ Multi-Cancer Early Detection Test detects more than 50 types of cancer, many of which are not commonly screened for today, through a simple blood draw. Current data suggest the the test can identify cancer 4 years before most current methods. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to other screening tests recommended by our healthcare provider.
The company’s list price cost for the test = $949. Your out of pocket price varies depending on insurance and your medical qualifications.
Click here for a Doctor Video visit to discuss these topics and order a test kit. $50/order (replaces your usual co-pay)
Important Safety Information
The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests. Results should be interpreted by a healthcare provider. A “cancer signal not detected” result does not rule out cancer. A “cancer signal detected” result requires confirmatory diagnostic evaluation (e.g. imaging), and if cancer is not confirmed, it may not be present, may not be detectable by diagnostic follow-up testing or may be located in a different part of the body. False-positive and false-negative test results do occur. Rx only.
After the doctor video visit you will receive a Test Requisition Form and a Kit will be mailed to you. Once you receive the kit please have your blood drawn by one of these service providers in your area. Get results within 10 business days of receipt of your blood tubes by GAIL Inc.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50–79 diagnosed 2006–2015 “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
- Noone AM, Howlader N, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer
Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website April 2018.
- Liu MC, Oxnard GR, Klein EA, et al.; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-59.
- Modeled detection extrapolated to 2020 US population ages 50–79. Screening includes methods with United States Preventive Services Task Force (USPSTF) A, B, or C rating (breast, colon, cervical, prostate, and lung), and assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 33% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).
- Data on file from Surveillance, Epidemiology, and End Results (SEER) 18 Regs Research Data, Nov 2017 Submission. Includes persons aged 50–79. Estimated deaths per year in 2020 from American Cancer Society Cancer Facts and Figures 2020. Available at: www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
- Klein E et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.